TABLE OF CONTENTS
| | | | Volume 31, Issue 1 (January 2017) | | In this issue Original Articles Letters to the Editor Correspondence Corrigendum
Also new AOP | | | | Original Articles | Top | | ACUTE MYELOID LEUKEMIA | Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD) OPENQ-Y Sun, L-W Ding, K-T Tan, W Chien, A Mayakonda, D-C Lin, X-Y Loh, J-F Xiao, M Meggendorfer, T Alpermann, M Garg, S-L Lim, V Madan, N Hattori, Y Nagata, S Miyano, A E J Yeoh, H-A Hou, Y-Y Jiang, S Takao, L-Z Liu, S-Z Tan, M Lill, M Hayashi, A Kinoshita, H M Kantarjian, S M Kornblau, S Ogawa, T Haferlach, H Yang and H P Koeffler Leukemia 2017 31: 1-10; advance online publication, June 8, 2016; 10.1038/leu.2016.160 Abstract | Full Text | | | | Subtype-specific patterns of molecular mutations in acute myeloid leukemiaD Rose, T Haferlach, S Schnittger, K Perglerová, W Kern and C Haferlach Leukemia 2017 31: 11-17; advance online publication, June 10, 2016; 10.1038/leu.2016.163 Abstract | Full Text | | | | Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study groupE Manara, G Basso, M Zampini, B Buldini, C Tregnago, R Rondelli, R Masetti, V Bisio, M Frison, K Polato, G Cazzaniga, G Menna, F Fagioli, P Merli, A Biondi, A Pession, F Locatelli and M Pigazzi Leukemia 2017 31: 18-25; advance online publication, June 28, 2016; 10.1038/leu.2016.177 Abstract | Full Text | | | | Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratioJ Versluis, F E M in ‘t Hout, R Devillier, W L J van Putten, M G Manz, M -C Vekemans, M -C Legdeur, J R Passweg, J Maertens, J Kuball, B J Biemond, P J M Valk, B A van der Reijden, G Meloni, H C Schouten, E Vellenga, T Pabst, R Willemze, B Löwenberg, G Ossenkoppele, F Baron, G Huls and J J Cornelissen Leukemia 2017 31: 26-33; advance online publication, June 24, 2016; 10.1038/leu.2016.183 Abstract | Full Text | | | | Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)W Blum, B L Sanford, R Klisovic, D J DeAngelo, G Uy, B L Powell, W Stock, M R Baer, J E Kolitz, E S Wang, E Hoke, K Mrózek, J Kohlschmidt, C D Bloomfield, S Geyer, G Marcucci, R M Stone, R A Larson and for the Alliance for Clinical Trials in Oncology Leukemia 2017 31: 34-39; advance online publication, September 13, 2016; 10.1038/leu.2016.252 Abstract | Full Text | | | | ACUTE LYMPHOBLASTIC LEUKEMIA | Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin OPENM N Cruickshank, J Ford, L C Cheung, J Heng, S Singh, J Wells, T W Failes, G M Arndt, N Smithers, R K Prinjha, D Anderson, K W Carter, A M Gout, T Lassmann, J O'Reilly, C H Cole, R S Kotecha and U R Kees Leukemia 2017 31: 40-50; advance online publication, June 13, 2016; 10.1038/leu.2016.165 Abstract | Full Text | | | | Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia OPENS Eldfors, H Kuusanmäki, M Kontro, M M Majumder, A Parsons, H Edgren, T Pemovska, O Kallioniemi, K Wennerberg, N Gökbuget, T Burmeister, K Porkka and C A Heckman Leukemia 2017 31: 51-57; advance online publication, July 27, 2016; 10.1038/leu.2016.202 Abstract | Full Text | | | | Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial OPENB Patel, A A Kirkwood, A Dey, D I Marks, A K McMillan, T F Menne, L Micklewright, P Patrick, S Purnell, C J Rowntree, P Smith and A K Fielding Leukemia 2017 31: 58-64; advance online publication, August 2, 2016; 10.1038/leu.2016.219 Abstract | Full Text | | | | CHRONIC MYELOGENOUS LEUKEMIA | Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cellsL Charaf, F-X Mahon, I Lamrissi-Garcia, I Moranvillier, F Beliveau, B Cardinaud, S Dabernat, H de Verneuil, F Moreau-Gaudry and A Bedel Leukemia 2017 31: 65-74; advance online publication, May 25, 2016; 10.1038/leu.2016.154 Abstract | Full Text | | | | The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatmentL N Eadie, P Dang, V A Saunders, D T Yeung, M P Osborn, A P Grigg, T P Hughes and D L White Leukemia 2017 31: 75-82; advance online publication, June 24, 2016; 10.1038/leu.2016.179 Abstract | Full Text | | | | LYMPHOMA | Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphomaA Bouska, W Zhang, Q Gong, J Iqbal, A Scuto, J Vose, M Ludvigsen, K Fu, D D Weisenburger, T C Greiner, R D Gascoyne, A Rosenwald, G Ott, E Campo, L M Rimsza, J Delabie, E S Jaffe, R M Braziel, J M Connors, C-I Wu, L M Staudt, F D‘Amore, T W McKeithan and W C Chan Leukemia 2017 31: 83-91; advance online publication, June 16, 2016; 10.1038/leu.2016.175 Abstract | Full Text | | | | MULTIPLE MYELOMA, GAMMOPATHIES | Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survivalE Muchtar, A Dispenzieri, S K Kumar, F K Buadi, M Q Lacy, S Zeldenrust, S R Hayman, N Leung, T V Kourelis, W Gonsalves, R Chakraborty, S Russell, D Dingli, J A Lust, Y Lin, P Kapoor, R Go, R A Kyle, S V Rajkumar and M A Gertz Leukemia 2017 31: 92-99; advance online publication, May 23, 2016; 10.1038/leu.2016.140 Abstract | Full Text | | | | Prognostic study for overall survival in patients with newly diagnosed POEMS syndromeC Wang, X-F Huang, Q-Q Cai, X-X Cao, M-H Duan, H Cai, D-B Zhou and J Li Leukemia 2017 31: 100-106; advance online publication, June 13, 2016; 10.1038/leu.2016.168 Abstract | Full Text | | | | A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS) OPENR Hájek, T Masszi, M T Petrucci, A Palumbo, L Rosiñol, A Nagler, K L Yong, A Oriol, J Minarik, L Pour, M A Dimopoulos, V Maisnar, D Rossi, H Kasparu, J Van Droogenbroeck, D B Yehuda, I Hardan, M Jenner, M Calbecka, M Dávid, J de la Rubia, J Drach, Z Gasztonyi, S Górnik, X Leleu, M Munder, M Offidani, N Zojer, K Rajangam, Y-L Chang, J F San-Miguel and H Ludwig Leukemia 2017 31: 107-114; advance online publication, June 24, 2016; 10.1038/leu.2016.176 Abstract | Full Text | | | | Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study OPENP Moreau, D Joshua, W-J Chng, A Palumbo, H Goldschmidt, R Hájek, T Facon, H Ludwig, L Pour, R Niesvizky, A Oriol, L Rosiñol, A Suvorov, G Gaidano, T Pika, K Weisel, V Goranova-Marinova, H H Gillenwater, N Mohamed, S Aggarwal, S Feng and M A Dimopoulos Leukemia 2017 31: 115-122; advance online publication, July 4, 2016; 10.1038/leu.2016.186 Abstract | Full Text | | | | Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patientsM Vignon, V Javaugue, M P Alexander, K El-Karoui, A Karras, D Roos-Weil, B Royer, B Asli, B Knebelmann, G Touchard, A Jaccard, B Arnulf, F Bridoux, N Leung and J P Fermand Leukemia 2017 31: 123-129; advance online publication, July 20, 2016; 10.1038/leu.2016.195 Abstract | Full Text | | | | Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progressionW I Gonsalves, S V Rajkumar, A Dispenzieri, D Dingli, M M Timm, W G Morice, M Q Lacy, F K Buadi, R S Go, N Leung, P Kapoor, S R Hayman, J A Lust, S J Russell, S R Zeldenrust, L Hwa, T V Kourelis, R A Kyle, M A Gertz and S K Kumar Leukemia 2017 31: 130-135; advance online publication, July 26, 2016; 10.1038/leu.2016.205 Abstract | Full Text | | | | Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis OPENH Landau, M Smith, C Landry, J F Chou, S M Devlin, H Hassoun, C Bello, S Giralt and R L Comenzo Leukemia 2017 31: 136-142; advance online publication, August 18, 2016; 10.1038/leu.2016.229 Abstract | Full Text | | | | MOLECULAR TARGETS FOR THERAPY | KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells OPENJ Etchin, A Berezovskaya, A S Conway, I A Galinsky, R M Stone, E Baloglu, W Senapedis, Y Landesman, M Kauffman, S Shacham, J C Y Wang and A T Look Leukemia 2017 31: 143-150; advance online publication, May 23, 2016; 10.1038/leu.2016.145 Abstract | Full Text | | | | Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemiasK Wang, M Sanchez-Martin, X Wang, K M Knapp, R Koche, L Vu, M K Nahas, J He, M Hadler, E M Stein, M S Tallman, A L Donahue, G M Frampton, D Lipson, S Roels, P J Stephens, E M Sanford, T Brennan, G A Otto, R Yelensky, V A Miller, M G Kharas, R L Levine, A Ferrando, S A Armstrong and A V Krivtsov Leukemia 2017 31: 151-158; advance online publication, June 13, 2016; 10.1038/leu.2016.166 Abstract | Full Text | | | | Restoration of MYC-repressed targets mediates the negative effects of GM-CSF on RUNX1-ETO leukemogenicityS Weng, S Matsuura, C T Mowery, S A Stoner, K Lam, D Ran, A G Davis, M-C Lo and D-E Zhang Leukemia 2017 31: 159-169; advance online publication, June 15, 2016; 10.1038/leu.2016.167 Abstract | Full Text | | | | Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcomeS Barrio, T D Shanafelt, J Ojha, K G Chaffee, C Secreto, K M Kortüm, S Pathangey, D L Van-Dyke, S L Slager, R Fonseca, N E Kay and E Braggio Leukemia 2017 31: 170-176; advance online publication, July 14, 2016; 10.1038/leu.2016.172 Abstract | Full Text | | | | MECHANISMS OF RESISTANCE | Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant OPENA Hamasy, Q Wang, K E M Blomberg, D K Mohammad, L Yu, M Vihinen, A Berglöf and C I E Smith Leukemia 2017 31: 177-185; advance online publication, May 25, 2016; 10.1038/leu.2016.153 Abstract | Full Text | | | | IMMUNOTHERAPY | Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectorsR Monjezi, C Miskey, T Gogishvili, M Schleef, M Schmeer, H Einsele, Z Ivics and M Hudecek Leukemia 2017 31: 186-194; advance online publication, June 24, 2016; 10.1038/leu.2016.180 Abstract | Full Text | | | | CYTOGENETICS AND MOLECULAR GENETICS | Exome sequencing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute erythroid leukemiaN Ping, A Sun, Y Song, Q Wang, J Yin, W Cheng, Y Xu, L Wen, H Yao, L Ma, H Qiu, C Ruan, D Wu and S Chen Leukemia 2017 31: 195-202; advance online publication, June 15, 2016; 10.1038/leu.2016.162 Abstract | Full Text | | | | INFECTIOUS MEDICINE, VIROLOGY | Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinibK-i Ishiyama, T Kitawaki, N Sugimoto, T Sozu, N Anzai, M Okada, M Nohgawa, K Hatanaka, N Arima, T Ishikawa, S Tabata, T Onaka, S Oka, Y Nakabo, R Amakawa, M Matsui, T Moriguchi, A Takaori-Kondo and N Kadowaki Leukemia 2017 31: 203-212; advance online publication, June 14, 2016; 10.1038/leu.2016.174 Abstract | Full Text | | | | ANIMAL MODELS | Induction of the 5S RNP–Mdm2–p53 ribosomal stress pathway delays the initiation but fails to eradicate established murine acute myeloid leukemiaP Jaako, A Ugale, M Wahlestedt, T Velasco-Hernandez, J Cammenga, M S Lindström and D Bryder Leukemia 2017 31: 213-221; advance online publication, June 3, 2016; 10.1038/leu.2016.159 Abstract | Full Text | | | | c-myb hyperactivity leads to myeloid and lymphoid malignancies in zebrafishW Liu, M Wu, Z Huang, J Lian, J Chen, T Wang, A Y H Leung, Y Liao, Z Zhang, Q Liu, K Yen, S Lin, L I Zon, Z Wen, Y Zhang and W Zhang Leukemia 2017 31: 222-233; advance online publication, June 14, 2016; 10.1038/leu.2016.170 Abstract | Full Text | | Letters to the Editor | Top | | Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic targetG Alatrash, H R Garber, M Zhang, P Sukhumalchandra, Y Qiu, H Jakher, A A Perakis, L Becker, S Y Yoo, K C Dwyer, K Coombes, A H Talukder, L S St John, V Senyukov, D A Lee, A Sergeeva, H He, Q Ma, P M Armistead, J Roszik, E A Mittendorf, J J Molldrem, D Hawke, G Lizee and S M Kornblau Leukemia 2017 31: 234-237; advance online publication, August 30, 2016; 10.1038/leu.2016.249 Full Text | | | | NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors OPENK Byrgazov, R Kastner, M Gorna, G Hoermann, M Koenig, C B Lucini, R Ulreich, M Benesch, V Strenger, H Lackner, W Schwinger, P Sovinz, O A Haas, M van den Heuvel-Eibrink, C M Niemeyer, O Hantschel, P Valent, G Superti-Furga, C Urban, M N Dworzak and T Lion Leukemia 2017 31: 237-240; advance online publication, August 30, 2015; 10.1038/leu.2016.250 Full Text | | | | A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphomaN M Reddy, J P Greer, D S Morgan, H Chen, S I Park and K L Richards Leukemia 2017 31: 241-244; advance online publication, September 22, 2016; 10.1038/leu.2016.255 Full Text | | | | Mutational profiling of a MonoMAC syndrome family with GATA2 deficiencyL-W Ding, T Ikezoe, K-T Tan, M Mori, A Mayakonda, W Chien, D-C Lin, Y-Y Jiang, M Lill, H Yang, Q-Y Sun and H P Koeffler Leukemia 2017 31: 244-245; advance online publication, September 29, 2016; 10.1038/leu.2016.256 Full Text | | | | Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasmsM Ruella, S S Kenderian, O Shestova, M Klichinsky, J J Melenhorst, M A Wasik, S F Lacey, C H June and S Gill Leukemia 2017 31: 246-248; advance online publication, September 28, 2016; 10.1038/leu.2016.262 Full Text | | | | The calcineurin protein phosphatase is dispensable for BCR-ABL-induced B-ALL maintenance, propagation and response to dasatinibF Rocchetti, C Tran Quang, A L Maragno, J Nguyen, C Lasgi and J Ghysdael Leukemia 2017 31: 248-251; advance online publication, October 3, 2016; 10.1038/leu.2016.269 Full Text | | | | Nuclear FOXM1 drives chemoresistance in AMLI Khan, M Halasi, M F Zia, P Gann, S Gaitonde, N Mahmud and A L Gartel Leukemia 2017 31: 251-255; advance online publication, October 3, 2016; 10.1038/leu.2016.270 Full Text | | | | CARMA1 is a novel regulator of T-ALL disease and leukemic cell migration to the CNS OPENS R Oruganti, D J Torres, S Krebsbach, F Asperti-Boursin, J Winters, K Matlawska-Wasowska, S S Winter, C Halsey and J L Cannon Leukemia 2017 31: 255-258; advance online publication, October 4, 2016; 10.1038/leu.2016.272 Full Text | | | | Expansion of Th1-like Vγ9Vδ2T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acidT Harada, H Miki, Q Cui, A Oda, R Amachi, J Teramachi, A Bat-Erdene, K Sogabe, M Iwasa, S Fujii, S Nakamura, K Kagawa, S Yoshida, I Endo, K Aihara, S Ozaki, T Matsumoto and M Abe Leukemia 2017 31: 258-262; advance online publication, October 4, 2016; 10.1038/leu.2016.273 Full Text | | | | Novel evidence that the mannan-binding lectin pathway of complement activation plays a pivotal role in triggering mobilization of hematopoietic stem/progenitor cells by activation of both the complement and coagulation cascades OPENM Adamiak, A Abdelbaset-Ismail, M Suszynska, A Abdel-Latif, J Ratajczak and M Z Ratajczak Leukemia 2017 31: 262-265; advance online publication, October 13, 2016; 10.1038/leu.2016.278 Full Text | | Correspondence | Top | | Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?V Némethová and F Rázga Leukemia 2017 31: 266-267; advance online publication, October 21, 2016; 10.1038/leu.2016.266 Full Text | | Corrigendum | Top | | Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinibK Ishiyama, T Kitawaki, N Sugimoto, T Sozu, N Anzai, M Okada, M Nohgawa, K Hatanaka, N Arima, T Ishikawa, S Tabata, T Onaka, S Oka, Y Nakabo, R Amakawa, M Matsui, T Moriguchi, A Takaori-Kondo and N Kadowaki Leukemia 2017 31: 268; 10.1038/leu.2016.188 Full Text | | | | | | | | | | | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com | | | | | | | | Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. | | | | |
No comments:
Post a Comment